Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Dec 14, 2023 5:24pm
134 Views
Post# 35785600

RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari
It's your impatience that is the problem.... wow I guess we can justify anything, we had mbc and have been patient for over 5 years since they had fda approval with a spa.
How about someone not exercising options that were supposedly in the money and letting them go so you don't have to hold shares and then getting awarded another 350,000 options. Why do they deserve this now when the sp was down 80% from our consolidation high, but I guess some can justify anytbiing. Has nothing to do with patience as we all know we have to wait for it to happen if it ever does, but really most must admit that the optics suck big time.
I am glad that some are ok with the sp down this low and no time frame for phase 3 for any trial  and for huge managment compensation and huge options with little or no shareholder value to show. And for allowing a hedge fund to be our biggest shareholder. I guess we are lucky that none of this matters. WE can pump or vent all we want but the sp does say it all right now and no denying that.
And yes we have great results but the numbers are very small so they will have to be ramped up one way or another either with the expanision of the existing trials or maybe just maybe we will actually get a panc phase 3 going sometime next year. A lot of anticipation for 2024 but then again we were supposed to have 2 phase 3 trials in 2023 and so we wait and hopefully don't get downgraded again by the analysts.
<< Previous
Bullboard Posts
Next >>